MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3265/nefrologia.pre2011.aug.11030

Медицинская библиотека · Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia · 2011

Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.

Hervás Sánchez José Gregorio, Prados Garrido María Dolores, Polo Moyano Aurora, Cerezo Morales Sebastian

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease. Treatment with paricalcitol, a selective vitamin D receptor (VDR) activator, has shown benefits in these patients by adequately reducing PTH levels with minimal changes in serum calcium and phosphorus. The aim of this study was to assess the effectiveness and safety of paricalcitol in chronic renal disease patients (CKD grades 3 and 4).

METHODS

A study of our experience with paricalcitol was conducted in normal clinical practice in patients over 18 years diagnosed with grade 3 or 4 chronic kidney disease. Patients were periodically evaluated every 3 months. The primary endpoint of effectiveness was to obtain two consecutive decreases of ≥30% in iPTH with respect to baseline values. The secondary endpoints were fulfilment of the objectives in accordance with the Spanish Society of Nephrology (SEN) and Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, as well as the relationship between the effectiveness of the treatment and different patient variables. Safety was studied by means of hypercalcaemia events.

RESULTS

The primary study endpoint was achieved in 54.3% of patients. In addition, another 16.3% of patients had reduced iPTH by more than 30% at the 3rd visit. Therefore, 70.6% of patients reduced their iPTH levels by more than 30% in 6 months. The relationship between treatment success and both glomerular filtration rate and body mass index was significant. There were few adverse events, although hypercalcaemia was found in 5.4% of patients.

CONCLUSIONS

Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin.

Для цитирования: Hervás Sánchez José Gregorio, Prados Garrido María Dolores, Polo Moyano Aurora, Cerezo Morales Sebastian. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2011. DOI: 10.3265/nefrologia.pre2011.aug.11030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.